Further analysis showed that PLOD2 was an adverse prognosis marker in lung adenocarcinoma patients at stage I but not at stage III (Figures 1d and e) and was independent of smoking history and gender (Supplementary Figures S1a and b). Here, PLOD2 is linked to lung adenocarcinoma.